Cite
MLA Citation
Niamh Appleby et al.. “Risk adjusted therapy in chronic lymphocytic leukemia: a phase II cancer trials Ireland (CTRIAL-IE [ICORG 07-01]) study of fludarabine, cyclophosphamide, and rituximab therapy evaluating response adapted, abbreviated frontline therapy with FCR in non-del(17p) CLL.” Leukemia & lymphoma, vol. 59, no. 6, 2018, pp. 1338–1347. http://access.bl.uk/ark:/81055/vdc_100064432671.0x000026